DR. DEEPASHRI MUTALIK

DR. CHAITRA JAYADEV, DR.NAVEEN KUMAR NAIK, DR.SANTOSH GOPI KRISHNA GADDE

Abstract

Aim: To evaluate the efficacy and safety of an intravitreal dexamethasone (DEX) implant in Indian patients with retinal vein occlusion (RVO) and macular edema.

Methods : 41 eyes of 41 patients in this study was included. Mean age was 61 years. There were 10 (24.3%), 29 (70.7%) and 2 (5%) cases of central, branch and hemi-central RVO, respectively. Mean corrected distance visual acuity at baseline was 0.60 +/- 0.41 logMAR. The CDVA and CFT values from the SD-OCT scans during each visit were analysed. The CDVA was analyzed at the 52 weeks follow up in eyes on DEX monotherapy. Other significant adverse events were noted.

Results : The highest improvement in mean corrected visual acuity noted at the 4 weeks follow-up (0.43 ± 0.26, p<0.05). The maximum reduction in the central foveal thickness was seen at the 4 weeks follow-up (p<0.05). Conclusion : Intravitreal DEX implant can be an effective and safe treatment for macular edema secondary to RVO, even in recalcitrant cases.